Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 17NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 1461Pancreatic Neoplasms 832Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 540Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 336Colonic Neoplasms 331Esophageal Neoplasms 297Liver Neoplasms 265Melanoma 255Lung Neoplasms 245Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 162Endometrial Neoplasms 160Rectal Neoplasms 159Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 104Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

pembrolizumab 1Taxes 1Pemetrexed 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hypopharyngeal Neoplasms × Gastrointestinal × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡